Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Respiratory Medicine

Topics

Medicine

Cancer Oncology

Internal Medicine

Pulmonary And Respiratory Medicine

Cancer Research

Show all topics

DOI

10.1016/s2213-2600(18)30264-9